Impaired Cholesterol Efflux Capacity of High-Density Lipoprotein Isolated From Interstitial Fluid in Type 2 Diabetes Mellitus—Brief Report

Apro, Johanna; Tietge, Uwe J. F.; Dikkers, Arne; Parini, Paolo; Angelin, Bo; Rudling, Mats

doi:10.1161/atvbaha.116.307385

Cited by 35 publications

(26 citation statements)

References 32 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diabetic dyslipidemia presents particularities regarding quantitative lipoprotein abnormalities and also qualitative and kinetic abnormalities that results in a more atherogenic lipid profile 28 . Changes in HDL composition in T2D have been shown to affect cholesterol efflux 42 , 43 . Moreover, higher proteinuria may increases the loss of particles derived from HDL catabolism 44 , 45 .…”

Section: Discussionmentioning

confidence: 99%

Circulating metabolic biomarkers of renal function in diabetic and non-diabetic populations

Barrios

Zierer

Würtz

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Using targeted NMR spectroscopy of 227 fasting serum metabolic traits, we searched for novel metabolic signatures of renal function in 926 type 2 diabetics (T2D) and 4838 non-diabetic individuals from four independent cohorts. We furthermore investigated longitudinal changes of metabolic measures and renal function and associations with other T2D microvascular complications. 142 traits correlated with glomerular filtration rate (eGFR) after adjusting for confounders and multiple testing: 59 in diabetics, 109 in non-diabetics with 26 overlapping. The amino acids glycine and phenylalanine and the energy metabolites citrate and glycerol were negatively associated with eGFR in all the cohorts, while alanine, valine and pyruvate depicted opposite association in diabetics (positive) and non-diabetics (negative). Moreover, in all cohorts, the triglyceride content of different lipoprotein subclasses showed a negative association with eGFR, while cholesterol, cholesterol esters (CE), and phospholipids in HDL were associated with better renal function. In contrast, phospholipids and CEs in LDL showed positive associations with eGFR only in T2D, while phospholipid content in HDL was positively associated with eGFR both cross-sectionally and longitudinally only in non-diabetics. In conclusion, we provide a wide list of kidney function–associated metabolic traits and identified novel metabolic differences between diabetic and non-diabetic kidney disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating metabolic biomarkers of renal function in diabetic and non-diabetic populations

Barrios

Zierer

Würtz

et al. 2018

Sci Rep

View full text Add to dashboard Cite

show abstract

“…For example, HDL isolated from interstitial fluid of subjects with type 2 diabetes was demonstrated to exhibit an impaired capacity to efflux cholesterol from lipid-loaded macrophages. 40 In another study, HDL from subjects with type 2 diabetics was impaired in its ability to protect against oxidative stress in cardiomyocytes through a mechanism that involves depletion of HDL-associated sphingosine-1-phosphate. 41 Interestingly, increased sphingolipids have recently been shown to be associated with symptomatic atherosclerotic plaques and inflammation in humans, 42 raising the possibility of interactions among HDL, sphingolipids and symptomatic lesions.…”

Section: Abnormal Lipoprotein Metabolism and Function In Macrovasculamentioning

confidence: 99%

Impact of Diabetes Mellitus

Kanter

Bornfeldt

2016

ATVB

View full text Add to dashboard Cite

“…107,121,122 Recent investigations suggest a role for impaired HDL function, with decreased cholesterol efflux capacity in diabetes. 123 However, to date pharmacologic means to raise HDL cholesterol levels have not been associated with both glucose lowering and improved cardiovascular outcomes, as discussed below in the section on non-statin lipid lowering trials.…”

Section: Mechanisms Of Increased Ascvd Risk and Mortality In Type 2 Dmentioning

confidence: 99%

Clinical Update: Cardiovascular Disease in Diabetes Mellitus

et al. 2016

View full text Add to dashboard Cite

Cardiovascular disease remains the principal cause of death and disability among patients with diabetes mellitus. Diabetes exacerbates mechanisms underlying atherosclerosis and heart failure. Unfortunately, these mechanisms are not adequately modulated by therapeutic strategies focusing solely on optimal glycemic control with currently available drugs or approaches. In the setting of multi-factorial risk reduction with statins and other lipid lowering agents, anti-hypertensive therapies, and anti-hyperglycemic treatment strategies, cardiovascular complication rates are falling, yet remain higher for patients with diabetes than for those without. This review considers the mechanisms, history, controversies, new pharmacologic agents, and recent evidence for current guidelines for cardiovascular management in the patient with diabetes mellitus to support evidence-based care in the patient with diabetes and heart disease outside of the acute care setting.

show abstract

Impaired Cholesterol Efflux Capacity of High-Density Lipoprotein Isolated From Interstitial Fluid in Type 2 Diabetes Mellitus—Brief Report

Abstract: Supplemental Digital Content is available in the text.

Cited by 35 publications

References 32 publications

Circulating metabolic biomarkers of renal function in diabetic and non-diabetic populations

Circulating metabolic biomarkers of renal function in diabetic and non-diabetic populations

Impact of Diabetes Mellitus

Clinical Update: Cardiovascular Disease in Diabetes Mellitus

Contact Info

Product

Resources

About